Novavax Shares Inc.
NVAX, + 4.41%
Thursday, 69% of the population in the pre-commercial trade, after the company said that a trial of treatment for the main cause of viral pneumonia in infants and young children does not occur. has not achieved its main objective. Novavax, based in Gaithersburg, Maryland, said the ResVax Phase 3 trial, a recombinant nanoparticle-based vaccine fusion protein (F) fused with Respiratory Syncytial Virus (RSV) with aluminum adjuvant , did not prevent a significant infection of the lower respiratory tract of RSV. The trial, however, has shown efficacy against a secondary goal of preventing hospitalization and is the first RSV vaccine to demonstrate phase 3 efficacy. The vaccine is being developed to protect infants by immunizing mothers against the disease, the leading cause of viral diseases of the lower respiratory tract in infants and young children. The VRS is the leading cause of hospitalization of infants in the United States, with an estimated annual rate of 76,000 people, the company said. "It is important to note that, even though this study did not meet the predefined success criterion for the primary endpoint of this trial, the data indicate that ResVax protects infants from some of the most severe consequences of RSV. including hospitalizations for RSV and hypoxemia, "said Stanley C. Erck, CEO of Novavax, in a statement. The company plans to meet with key regulators to discuss its next steps. Novavax shares fell 1.8% in the last 12 months up to Wednesday, while the S & P 500 index
Have the latest news sent to your inbox. Subscribe to free e-mails from the MarketWatch newsletter. Register here.